|
|
|
|
|
|
|
PEER-TO-PEER CLINICAL CONVERSATIONS |
|
|
|
|
|
|
Decoding Exceptional Responses: The National Cancer Institute's Unique Prostate Cancer Study
|
Fatima Karzai, MD, and Rana McKay, MD
Alicia Morgans hosts Fatima Karzai and Rana McKay to explore the National Cancer Institute Natural History Study. This study focuses on prostate cancer patients with unusual mutations and exceptional responses to treatments, aiming to understand their disease progression over time.
|
|
|
|
|
|
|
|
|
|
|
|
Genomic Alterations and Lutetium PSMA Response in Prostate Cancer
|
Alexandra Sokolova, MD
Alexandra Sokolova discusses her team's study on genomic alterations influencing the response to lutetium-177 PSMA in metastatic castration-resistant prostate cancer. Their research highlights the need for better biomarkers to predict patient outcomes with lutetium-177 PSMA, as not all patients respond to this treatment.
|
|
|
|
|
|
|
|
|
|
|
| Cancer Origin Tracing and Timing in Two High-Risk Prostate Cancers Using Multisample Whole Genome Analysis: Prospects for Personalized Medicine - Beyond the Abstract
|
| Anssi Nurminen, Serafiina Jaatinen, Sinja Taavitsainen et al.
|
| An international team led by researchers from Tampere, Finland, used multisample whole genome analysis to trace the origins, growth, and spread of two high-risk prostate cancers. They analyzed 22 sequenced sites, mapping genetic drivers and distinguishing metastatic from non-metastatic subclones. The study found that metastasis occurred ipsilaterally from prostate to lymph nodes, enhancing the identification of key genetic drivers and informing better therapy selection.
|
|
|
|
|
|
| A Multi-Center Natural History Study of Precision-Based Genomics in Prostate Cancer
|
| Fatima Karzai MD
|
| Fatima Karzai presents a multicenter study on precision-based genomics in prostate cancer. This prospective cohort study aims to collect clinical and genomic data to understand the natural history of prostate cancer with specific molecular alterations and exceptional responses. The study seeks to identify new biomarkers and predictive patterns, enhancing precision management strategies for the disease.
|
|
|
|
|
|
|
|
|
|
|
| Definitions of Disease Burden Across the Spectrum of Metastatic Castration-Sensitive Prostate Cancer: Comparison by Disease Outcomes and Genomics - Beyond the Abstract
|
| Matthew Deek, Philip Sutera, Kim Van Der Eecken et al.
|
| Recent research suggests metastatic castration-sensitive prostate cancer (mCSPC) exists on a spectrum rather than as a binary state, leading to classifications into high- and low-volume states to improve treatment and risk stratification. Evaluating four definitions (CHAARTED, STAMPEDE, oligometastatic ≤3, and oligometastatic ≤5), the study found they effectively stratify patients by outcomes and revealed similar genetic profiles across these classifications
|
|
|
|
|
|
| Activity of Lutetium-177 Prostate-Specific Membrane Antigen and Determinants of Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Previously Treated with Cabazitaxel: The PACAP Study - Beyond the Abstract
|
| Ronan Flippot, MD, MSc
|
| The VISION trial was the first phase 3 study to demonstrate an overall survival benefit for PSMA-targeted radioligand therapy lutetium-177 Lu-PSMA-617 (Lu-PSMA) over the standard of care in patients with castration-resistant prostate cancer previously treated with chemotherapy and second-generation novel hormonal agents (NHA). Following these results, Lu-PSMA has been approved in most European countries in this population.
|
|
|
|
|
|
| Novel Approaches of Combination PSMA-Based Radiopharmaceutical Treatments for Prostate Cancer
|
| James Buteau, MD, FRACP, FRCPC
|
| James Buteau discusses novel PSMA-based radiopharmaceutical treatments for prostate cancer. Highlights included three trials: VIOLET, evaluating Terbium-161-PSMA-I&T; AlphaBet, combining Radium-223 with Lutetium-177 PSMA-I&T; and LuCAB, combining cabazitaxel with Lutetium-177 PSMA-617. These studies aim to improve treatment efficacy and patient outcomes in metastatic castration-resistant prostate cancer.
|
|
|
|
|
|
|
|
|
|
|
